Work

Abstract CT162: Pre-specified interim analysis in a prospective, randomized phase II trial of trastuzumab vs trastuzumab + NeuVax to prevent breast cancer recurrence in HER2+ breast cancer patients

Year: 2017

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2017-ct162

Authors: Kaitlin M. Peace, Jennifer K. Litton, Rashmi Murthy, Timothy J. Vreeland, Diane F. Hale, Doreen O. Jackson, John S. Berry, Alfred F. Trappey, Garth S. Herbert, Guy T. Clifton, Mark O. Hardin, George E. Peoples, Elizabeth A. Mittendorf

Institutions: Brooke Army Medical Center, The University of Texas MD Anderson Cancer Center, Womack Army Medical Center, Washington University in St. Louis, Madigan Army Medical Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2740715217

Cites:

Cited by: 1

Related to: 10